(amended)1. A composition comprising immunosuppressants, cyclosporins, FK506, or rapamycin and at least one bioactive peptide corresponding to the high-affinity binding/anti-lymphoproliferative site of interferons a,b,w,t, or recombinant proteins carrying one or more of the sequences corresponding to the structures of the bioactive peptides corresponding to the high-affinity binding/anti-lymphoproliferative site of the said interferons for the aim of amplification of immunosuppressants' activities to decrease their therapeutic dose, and as the consequence to avoid their undesirable side effects during organ and tissue transplantation or during treatment of cancers such as lymphomas, leukemias, myelomas, adenocarcinomas, autoimmune and chronic inflammatory diseases, such as rheumatoid arthritis, myasthenia gravis, lupus erythematosis, uveitis, hyperproliferative diseases, such as psoriasis vulgaris, wherein cyclosporins, FK506 or rapamycin can be exploited.

(amended)3. The composition according to Claim 1 comprising at least one immunosuppressant cyclosporins, FK506 or rapamycin, and at least one recombinant protein comprising one or more of the sequences of SEQ ID NO 1 or a variant thereof that is SEQ ID NO 2, such that at up to three amino acids of SEQ ID NO 1 are substituted.

(amended)4. The composition according to Claim 5 wherein the at least one peptide is genetically or chemically modified or genetically or chemically or physically bound to a small-molecular or macromolecular substance increase the stability of the at least one peptide in physiological conditions or for regulating the bioavailability of the at least one peptide.

Please add the following claims:

5. The composition according to claim 1, comprising at least one cyclosporin, rapamycin or FK506 and at least one peptide having the amino acid sequence of SEQ ID NO. 1 or being a variant of SEQ. ID NO. 1 that is SEQ. ID. NO. 2 such that zero to three amino acids of SEQ ID NO. 1 are substituted.

6. A pharmaceutical composition comprising an immunosuppressant selected from at least one cyclosporin, FK506 or rapamycin, and at least one bioactive polypeptide that comprises a peptide that inhibits T-lymphoblastoid cell proliferation induced by phytohemagglutinin.

7. The composition according to claim 6, wherein the at least one bioactive polypeptide is an 8-mer.

8. The composition according to claim 6, wherein the at least one peptide has the amino acid sequence of SEQ ID NO. 1 or a variant of SEQ. ID NO. 1 that is SEQ. ID. NO. 2 such that zero to three amino acids of SEQ ID NO. 1 are substituted.

9. The composition according to claim 6, wherein the peptide has the amino acid sequence of SEQ ID NO. 1.

10. The composition according to claim 6, wherein the at least one bioactive polypeptide has the amino acid sequence of SEQ ID NO. 1.

11. The composition according to claim 6, wherein the at least one bioactive polypeptide is a-peptoferon, albeferon, albebetin or a mixture thereof.

12. A method for amplifying the activity of an immunosuppressant comprising administering to a subject to whom an immunosuppressant has been, is or will be administered, at least one bioactive polypeptide that comprises a peptide that inhibits T-lymphoblastoid cell proliferation induced by phytohemagglutinin.

13. The method according to claim 12, wherein the at least one bioactive polypeptide is an 8-mer.

14. The method according to claim 12, wherein the at least one peptide has the amino acid sequence of SEQ ID NO. 1 or a variant of SEQ. ID NO. 1 that is SEQ. ID. NO. 2 such that zero to three amino acids of SEQ ID NO. 1 are substituted.

15. The method according to claim 12, wherein the peptide has the amino acid